NCT01613300View on ClinicalTrials.gov

Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 4, 2012

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2020

Conditions

B-Cell Lymphomas

Interventions

DRUG

Ofatumumab

Ofatumumab as part of the reduced intensity conditioning regimen (RIC)

Trial Locations (10)

29010

Complejo Hospitalario Carlos Haya, Málaga

41013

Hospital Virgen del Rocío, Seville

Unknown

Hospital Vall d'Hebron, Barcelona

Hospital Reina Sofia, Córdoba

H.U. 12 de Octubre,, Madrid

H.U. Gregorio Marañón,, Madrid

H.U. La Paz, Madrid

H. Morales Meseguer., Murcia

H. Clinico de Salamanca, Salamanca

H. La Fe, Valencia

All Listed Sponsors

lead

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

OTHER

NCT01613300 - Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients | Biotech Hunter | Biotech Hunter